Shire is reportedly in advanced talks to acquire Baxter’s biopharma spin-off Baxalta and may announce a deal this week.
According to Bloomberg, sources familiar with the matter have said that the Irish firm could buy Baxalta for $32 billion, or $46.50-$48 a share. The deal is expected to contain a cash component.
After Baxalta’s management rejected an initial bid, Shire went public with a $30 billion unsolicited offer in August 2015, only a month after Baxalta was spun off from Baxter.
After shareholders agreed with the board that this offer was too low, rumours swelled in November that Shire was looking to make a second approach and had asked its advisers to construct a new deal.
Flemming Ornskov, chief executive officer of Shire, has said that the companies could deliver $20 billion in product sales by 2020.
By George Underwood
Source: Pharma Times
The deal inked with New York-based Ovid Therapeutics carries an almost $200 million upfront payment and could be worth as much as $856 million provided the medicine, known as soticlestat, hits certain milestones.
Novartis has entered an initial agreement to manufacture the mRNA and bulk drug product for CureVac’s Covid-19 vaccine candidate, CVnCoV.
A whole new world: Philips and the Walt Disney Company will use animated shorts featuring some of Disney’s most famous characters in customized stories created with clinical guidance from Philips.